Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

In essence, adverse medical conditions frequently correlated with elevated serum OPG levels.Baseline characteristics of study participants by serum OPG levels.Serum OPG levelsP valueQ1Q2Q3Q4Follow-up duration (years)7.705 ± 2.5877.426 ± 2.6686.983 ± 2.9976.444 ± 3.094 < 0.001Age (years)43.859 ± 10.89851.338 ± 10.73456.309 ± 10.46362.672 ± 8.186 < 0.001Male185 (35.2)223 (42.2)216 (40.9)199 (37.8)0.090Charlson comorbidity index < 0.001 0 to 3496 (94.5)436 (82.4)357 (67.6)208 (39.5) 4 to 529 (5.5)90 (17.0)156 (29.5)301 (57.1) 6 to 70 (0.0)3 (0.6)15 (2.8)17 (3.2) ≥ 80 (0.0)0 (0.0)0 (0.0)1 (0.2)Primary renal disease < 0.001 DM25 (4.8)87 (16.4)143 (27.2)277 (52.6) HTN91 (17.3)104 (19.7)129 (24.5)94 (17.8) GN247 (47.0)197 (37.2)149 (28.3)72 (13.7) TID4 (0.8)2 (0.4)3 (0.6)5 (0.9) PKD124 (23.6)105 (19.8)75 (14.3)36 (6.8) Others34 (6.5)34 (6.4)27 (5.1)43 (8.2)Smoking status0.056 Non-smoker285 (54.3)284 (53.8)284 (54.0)269 (51.0) Ex-smoker98 (18.7)92 (17.4)69 (13.1)79 (15.0) Current smoker142 (27.0)152 (28.8)173 (32.9)179 (34.0)Medication ACEIs/ARBs455 (86.7)455 (86.2)456 (86.5)436 (82.7)0.214 Diuretics103 (19.6)144 (27.3)180 (34.2)246 (46.7) < 0.001 Statins221 (42.1)265 (50.2)303 (57.5)308 (58.4) < 0.001 Antiplatelets/anticoagulants90 (17.1)141 (26.7)164 (31.1)202 (38.3) < 0.001BMI (kg/m2)24.618 ± 3.60024.604 ± 3.47324.659 ± 3.41724.414 ± 3.0850.607WHR0.883 ± 0.0670.893 ± 0.0630.904 ± 0.0650.914 ± 0.063 < 0.001SBP (mmHg)124.368 ± 14.616126.602 ± 14.324127.472 ± 15.673132.608 ± 18.619 < 0.001DBP (mmHg)77.663 ± 10.78778.146 ± 10.45476.442 ± 10.82975.759 ± 12.2470.002Laboratory findings Hemoglobin (g/dL)13.797 ± 1.84813.174 ± 1.92712.713 ± 1.90711.654 ± 1.776 < 0.001 Albumin (g/dL)4.303 ± 0.3474.227 ± 0.3854.179 ± 0.4033.987 ± 0.496 < 0.001 Total cholesterol (mg/dL)175.326 ± 33.617176.053 ± 39.909174.918 ± 42.788170.998 ± 40.2280.164 HDL-C (mg/dL)50.442 ± 15.03651.409 ± 15.77148.723 ± 15.51546.864 ± 15.464 < 0.001 LDL-C (mg/dL)98.451 ± 28.52698.528 ± 33.03596.324 ± 34.00494.441 ± 31.5210.109 TG (mg/dL)155.374 ± 97.262147.515 ± 83.379166.666 ± 113.581161.097 ± 100.5080.011 Fasting glucose (mg/dL)101.237 ± 22.014105.522 ± 30.181113.065 ± 40.451123.380 ± 54.767 < 0.001 25(OH)D18.479 ± 7.32418.154 ± 7.15617.813 ± 7.31817.115 ± 9.5820.064 hs-CRP (mg/dL)0.500 [0.200, 1.300]0.680 [0.300, 1.550]0.695 [0.300, 1.800]0.700 [0.230, 2.100]0.034 Spot urine ACR (mg/g)197.628 [32.628, 599.759]293.761 [52.457, 761.677]391.228 [92.824, 1106.630]716.078 [198.801, 1926.921] < 0.001 Creatinine (mg/dL)1.378 ± 0.9661.567 ± 0.9201.856 ± 1.0522.481 ± 1.321 < 0.001 eGFR (mL/min./1.73 m2)67.953 ± 32.40956.806 ± 30.76645.015 ± 24.11231.637 ± 18.399 < 0.001CKD stages < 0.001 Stage 1175 (33.3)108 (20.4)45 (8.5)12 (2.3) Stage 2146 (27.8)130 (24.6)92 (17.4)30 (5.7) Stage 3a88 (16.8)91 (17.2)102 (19.3)65 (12.3) Stage 3b68 (13.0)107 (20.2)142 (26.9)126 (23.9) Stage 441 (7.8)77 (14.6)120 (22.7)214 (40.6) Stage 57 (1.3)16 (3.0)27 (5.1)80 (15.2)Values for categorical variables are given as number (percentage); values for continuous variables, as mean ± standard deviation or median [interquartile range]. 25(OH)D 25-hydroxyvitamin D, ACEIs angiotensin converting enzyme inhibitors, ACR albumin-to-creatinine ratio, ARBs angiotensin receptor blockers, BMI body mass index, CKD chronic kidney disease, DBP diastolic blood pressure, DM diabetes mellitus, eGFR estimated glomerular filtration rate, GN glomerulonephritis, HDL-C high-density lipoprotein cholesterol, hs-CRP high-sensitivity C-reactive protein, HTN hypertension, LDL-C low-density lipoprotein cholesterol, OPG osteoprotegerin, PKD polycystic kidney disease, Q1 1st quartile, Q2 2nd quartile, Q3 3rd quartile, Q4 4th quartile, SBP systolic blood pressure, TG triglyceride, TID tubulointerstitial disease, WHR waist-to-hip ratio.

Source: Baseline characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Throughout the study, participants were closely monitored, with outcome events recorded by the clinical determination of the investigators at each center.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Circulating osteoprotegerin levels and cardiovascular outcomes in patients with pre-dialysis chronic kidney disease: results from the KNOW-CKD study

Study design awaiting verification · Scientific Reports · 2024

Original publication title

Circulating osteoprotegerin levels and cardiovascular outcomes in patients with pre-dialysis chronic kidney disease: results from the KNOW-CKD study

Sang Heon Suh; Tae Ryom Oh; Hong Sang Choi; Chang Seong Kim; Eun Hui Bae; Seong Kwon Ma; Kook-Hwan Oh; Kyu-Beck Lee; Jong Cheol Jeong; Ji Yong Jung; Soo Wan Kim; The Korean Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD) Investigators

© The Author(s) 2024

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

While the relationship between circulating osteoprotegerin (OPG) and cardiovascular events is well-established in the general population, its association with cardiovascular risks in chronic kidney disease (CKD) patients remains less robust. This study hypothesized that elevated circulating OPG levels might be associated with an increased risk of major adverse cardiac events (MACE) in CKD patients, a total of 2,109 patients with CKD stages 1 through pre-dialysis 5 from the KNOW-CKD cohort were categorized into quartiles based on serum OPG levels. The primary outcome of the study was 3-point MACE, defined as a composite of nonfatal myocardial infarction, nonfatal stroke, or cardiac death.

The median follow-up duration was 7.9 years. The cumulative incidence of 3-point MACE significantly varied across serum OPG levels in Kaplan: Meier curve analysis (P < 0.001, log-rank test), with the highest incidence observed in the 4th quartile. Cox regression analysis indicated that, relative to the 1st quartile, the risk of 3-point MACE was significantly higher in the 3rd (adjusted hazard ratio 2.901, 95% confidence interval 1.009 to 8.341) and the 4th quartiles (adjusted hazard ratio 4.347, 95% confidence interval 1.410 to 13.395).

In conclusion, elevated circulating OPG levels are associated with adverse cardiovascular outcomes in pre-dialysis CKD patients.

Authors’ abstract

While the relationship between circulating osteoprotegerin (OPG) and cardiovascular events is well-established in the general population, its association with cardiovascular risks in chronic kidney disease (CKD) patients remains less robust. This study hypothesized that elevated circulating OPG levels might be associated with an increased risk of major adverse cardiac events (MACE) in CKD patients, a total of 2,109 patients with CKD stages 1 through pre-dialysis 5 from the KNOW-CKD cohort were categorized into quartiles based on serum OPG levels. The primary outcome of the study was 3-point MACE, defined as a composite of nonfatal myocardial infarction, nonfatal stroke, or cardiac death.

The median follow-up duration was 7.9 years. The cumulative incidence of 3-point MACE significantly varied across serum OPG levels in Kaplan: Meier curve analysis (P < 0.001, log-rank test), with the highest incidence observed in the 4th quartile. Cox regression analysis indicated that, relative to the 1st quartile, the risk of 3-point MACE was significantly higher in the 3rd (adjusted hazard ratio 2.901, 95% confidence interval 1.009 to 8.341) and the 4th quartiles (adjusted hazard ratio 4.347, 95% confidence interval 1.410 to 13.395).

In conclusion, elevated circulating OPG levels are associated with adverse cardiovascular outcomes in pre-dialysis CKD patients.

Publication and source details

Original title: Circulating osteoprotegerin levels and cardiovascular outcomes in patients with pre-dialysis chronic kidney disease: results from the KNOW-CKD study

Sang Heon Suh; Tae Ryom Oh; Hong Sang Choi; Chang Seong Kim; Eun Hui Bae; Seong Kwon Ma; Kook-Hwan Oh; Kyu-Beck Lee; Jong Cheol Jeong; Ji Yong Jung; Soo Wan Kim; The Korean Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD) Investigators

Scientific Reports · 2024

© The Author(s) 2024https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT)RS-2023-00278258RS-2023-00217317Suh Sang Heon Kim Soo Wan the Research Program funded by the Korea Disease Control and Prevention Agency2011E33003002012E33011002013E33016002013E33016012013E33016022016E33002002016E33002012016E33002022019E3201002019E3201012019E3201022022-11-007Oh Kook-Hwan

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T12:58:59.026667+00:00

DOI: 10.1038/s41598-024-54335-y · PMC10876961